Tesamorelin
Tesamorelin Acetate
A synthetic growth hormone releasing factor analog specifically FDA-approved for reducing excess abdominal fat in HIV-associated lipodystrophy.
Typical Cost
$600-1200/month (prescription)
Status
Research
Peptide Profile
Tesamorelin
Mechanism of Action
Stimulates pulsatile release of growth hormone from the pituitary. More targeted toward visceral fat reduction than other GHRH analogs. Improves lipid profiles and reduces inflammatory markers.
Common Dosages
subcutaneous
2mg
Daily · 3-6 months
Benefits
Reduced visceral fat
Improved lipid profile
Better insulin sensitivity
Preserved lean mass
Enhanced quality of life
Side Effects
Injection site reactions
Joint pain
Muscle aches
Peripheral edema
Increased blood sugar
Key Research
Tesamorelin in HIV lipodystrophy
Demonstrated significant reduction in visceral adipose tissue compared to placebo
Regulatory Status
FDA-approved (Egrifta) for HIV-associated lipodystrophy. Prescription required.
Contraindications
- ⚠Active malignancy
- ⚠Pregnancy/breastfeeding
- ⚠Diabetic retinopathy
For GLP-1 users targeting stubborn visceral fat, tesamorelin offers a clinically-validated approach alongside SeraVia's metabolic support formulations.
Learn More →Find peptide providers
Search 18,000+ clinics offering peptide therapy alongside GLP-1 medications.
Search Providers →Disclaimer: This information is for educational and research purposes only. Peptides described here may not be FDA-approved for human use. Always consult a qualified healthcare provider before using any peptide product. GLP1Search does not sell peptides.